Radiopharm Theranostics Limited has released a press release.
RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial
Earlier from Radiopharm Theranostics
- Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
- RAD to meet with US FDA to align on RAD 101 Phase 3 Trial
- Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up to Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
- RAD completes A$12.5 M placement and launches A$6 M SPP